A Guideline for the Management of Gastrointestinal Stromal
Tumour (GIST) by Judson, Ian et al.
Introduction
In early  2002  a  group of  UK  investigators, either
members  of  the  European  Organisation  and
Treatment of Cancer (EORTC) Soft  Tissue and Bone
Sarcoma  Group  (STBSG)  and/or  the  National
Cancer Research Institute Sarcoma Group,UK (cur-
rent Chair IJ), with experience in the use of imatinib
for the treatment of gastrointestinal stromal tumours
(GIST) agreed to develop guidelines for the manage-
ment of GIST, including how to incorporate the use
of this drug into UK clinical practice. A licence was
granted this year for the treatment of patients with
advanced, unresectable or metastatic GIST, on the
basis of the data from the Phase II study conducted in
the USA.Imatinib is an expensive agent but,owing to
its high level of activity in this setting,there is consid-
erable  pressure on physicians  and  health  commis-
sioners to make the drug available.This guideline is
the result of  extensive discussion and consultation
with  medical  oncologists, clinical  oncologists, sur-
geons, and pathologists involved in the management
of sarcoma.We have tried to set out recommendations
that should help limit inappropriate use of the drug,
while at the same time recognising its undoubted util-
ity for patients with advanced GIST.
Gastro-intestinal  stromal  tumours  are  mesen-
chymal  cancers  (sarcomas)  that  arise  from  the
connective  tissues  of  the  gastro-intestinal  tract.
Although rare, they are nevertheless the commonest
sarcomas  to  arise  in  the  gut. The  incidence  of 
GIST is uncertain but appears to be in the region of
10  per  million  per  year, i.e. 500–1000  patients  a 
year  in  the  UK. These  tumours  were  previously 
classi￿ ed  as  leiomyosarcoma, but  in  recent  years 
it  has  become  accepted  that  they  are  a  distinct 
entity  and  can  usually  be  distinguished  from
leiomyosarcoma  by  expression  of  the  cell  surface
markers  CD34  and  CD117. These  markers  are
shared with the  interstitial  cells of  Cajal, or pace-
maker cells and it has been suggested that  GISTs
arise from Cajal cells or a common progenitor cell.1,2
Cajal cells form a network in the myenteric plexus of
the gut and have a role in the coordination of peri-
stalsis.
GISTs commonly have gain of function mutations
in the KIT gene that codes for the KIT receptor tyro-
sine kinase. This is the receptor for stem cell factor
and is designated CD117 in terms of immunohisto-
chemistry.The commonest exon 11 mutations allow
receptor  dimerisation  in  the  absence  of  stem  cell
factor, making the signalling pathway independent of
external in￿ uence.3 GISTs have different degrees of
aggressiveness, resulting in variation in their poten-
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Patients  with  surgically  resectable  GISTs  have  a 
10-year survival rate of 30–50%.The median survival
of  patients  with  surgically  unresectable, metastatic
and  advanced  sarcomas of  soft  tissue is  about  12
months.4 Experience has shown that these tumours
are even less responsive to chemotherapy than other
sarcomas, with a response rate estimated at <5%,5 in
other words the standard chemotherapy agents used
for  other sarcomas, such  as  doxorubicin and ifos-
famide, have  no  place  in  the  management  of  the
disease.
Imatinib
Imatinib  (Glivec, STI 571)  was  granted  a  licence 
in the EU for the treatment of advanced unresectable
or metastatic GIST in May 2002. A dose of 400 or
600 mg daily is recommended, based on data from
the US Phase II trial, which explored these doses. It
is acknowledged that  the  optimum dose may  vary
from patient to patient. Imatinib is an orally admin-
istered, selective  inhibitor  of  the  BCR-ABL, KIT,
PDGF-R and ARG tyrosine kinases. Phase I, II and
III trials have consistently shown that the majority of
patients  with  locally  advanced  unresectable  or
metastatic  disease  bene￿ t  from  treatment  with
imatinib.Imatinib is generally given at a starting dose
of 400 mg/day orally for chronic myeloid leukaemia
(CML), for  which  it  was  licensed  in  November 
2001. NICE  recently  published  a  ￿ nal  appraisal
determination  on  the  use  of  imatinib  in  chronic
myeloid  leukaemia  (http://www.nice.org.uk)  taking
into account results from a  trial indicating a  high 
incidence  of  complete  cytogenetic  response, 85%
progression-free  and  91%  overall  survival  at  24
months in chronic phase patients receiving imatinib.
The  of￿ cial guidance on which  groups of patients 
are to be recommended treatment with imatinib will
be published shortly. The issue of the most appro-
priate dose for GIST is discussed below but there are
some  data  indicating  that  larger  doses  might  be
necessary for optimal treatment of GIST compared
with CML.
Research data in support of the use of imatinib in
GIST
Imatinib was developed as an inibitor of BCR-ABL
for the treatment of chronic myeloid leukaemia and
has proved highly effective against the disease. It was
recognised that functional expression of the receptor
tyrosine kinase KIT in GIST, often due to activating
mutations in KIT, might make imatinib a useful drug
in this setting.A single patient with GIST was treated
successfully  in  the  Spring  of  2000, clinical  trials
began in the USA in July and in Europe in August
2000. A Phase II study in the USA compared 400
with 600 mg daily.Those progressing on 400 mg/day
were transferred to 600 mg.Thirty-￿ ve patients were
evaluable. Partial responses, assessed at 1–3 months,
were seen in 19 patients (54%), stable disease in 12
(34%). Four  patients  (11%)  progressed. Median
survival had not yet been reached (patient recruit-
ment from July to September 2000) at the time of
study report.6
A Phase I study in Europe studied doses of 400,
600, 800  or  1000  mg  daily, in  40  patients  with
advanced  soft  tissue  sarcomas  (36  of  whom  had
GISTs).Preliminary data were reported in November
2001.7Tumour inhibition was seen in 30 patients with
GIST, with 19 con￿ rmed partial responses and six
uncon￿ rmed  partial  responses. A  recent  update
demonstrated  that  29  (80%)  of  the  patients  with
GIST were still on treatment after a minimum of 11
month.8 Doses of 1000 mg/day were likely to cause
dose-limiting side effects,but 800 mg daily was feasi-
ble.The commonest side effects were skin rash, nau-
sea  and  vomiting, oedema  and  fatigue. Some
myelosuppression was seen but this was rarely dose-
limiting. FDG-PET scan responses a week after the
start  of  treatment  predicted subsequent computed
tomography (CT) responses.
A Phase II study was performed at 800 mg daily in
patients with GIST and other soft tissue sarcomas,
and was reported at the recent American Society of
Clinical Oncoloy meeting.9 A response rate of 71%
(one  complete  and  18  partial  remissions)  was
demonstrated  in  the  GIST  patients, whereas  no
objective  remissions  were  observed  in  other
sarcomas. Most notable was the fact that only 11%
of patients with GIST progressed during the ￿ rst 8
weeks  of  therapy, whereas  the  progression rate  in
other sarcomas was 71%.Although it has been noted
that GIST tumours may become less radiodense on
CT scan at an early stage,objective responses may be
slow  to  materialise, sometime  occurring  many
months later, with a median time to remission of 4
months. Serious side effects were rare and grade 2
toxicities  other than  anaemia, oedema and fatigue
occurred in less than 10% of patients. Most toxicities
tended  to  diminish  in  severity  with  time. With
complete data available at a minimum of 11 months
of follow-up,73% of patients were free from progres-
sion at 12 months. Overall survival at 12 months was
>95%. Phase III trials comparing 400 and 800 mg
daily have been performed in the USA, coordinated
by  the  National  Cancer  Institute, and  in  Europe,
conducted  by  the  European  Organisation  for
Research and Treatment of Cancer, both of which
have now closed. To date only safety data are avail-
able, indicating  that  imatinib  is  an  extremely  safe
medication.10,11 A similar level of clinical bene￿ t in
the Phase III trial has been observed by individual
investigators, to that reported in the original Phase I
and Phase II trials.
It  is  clear  from  the  limited  data  available  that
median survival for patients requiring treatment has
increased from under a year to well over a year.In the
84 I.Judson et al.original Phase  I  trial, the  study that  currently has 
the  longest  follow-up, the  updated  information
presented  at  the  American  Society  of  Clinical
Oncology meeting (Orlando, FL, May 2002), 27 of
35  (77%)  patients  with  GIST  were  still  receiving
treatment at 16 months minimum follow-up. These
patients were either in partial remission or had stable
disease, four of them had required a dose escalation
in order to regain control of their disease. Five had
relapsed and died after an initial response or disease
stabilisation. Symptomatic  bene￿ t  in  that  study 
was 80%.7
It must be emphasised that these ￿ gures fail to do
justice to the dramatic improvements that have been
seen. Imatinib clearly causes rapid tumour cell kill in
many patients, who experience rapid relief of pain,
abdominal distension and anorexia.Weight gain can
be  dramatic and some patients  have been rescued
from  terminal cancer cachexia, at  a  stage  in their
disease when they had already lost more than 25% 
of their body weight, with serum albumin values of
signi￿ cantly less than 30 g/l. In this situation, sur-
vival  can usually be  measured in weeks but  many 
of these patients remain alive and well, often in full
time  employment, a  year  or  more  after  starting 
treatment.
Additional  studies  are  required  to  advance  our
understanding  of  what  constitutes  the  optimum 
dose for treatment of advanced disease and the role
of KIT mutations in determining response or resis-
tance. However, it  was  reported that  two  patients
progressing on 400 mg had disease stabilisation on
800  mg  daily,11 and  patients  relapsing  after  an 
initial  good  response  may  also  sometimes  be
stabilised on a higher dose (van Oosterom, ASCO,
2002). The  updated  response  rate  of  71%  in  the 
800-mg daily Phase II study might also indicate the
presence of a dose–response relationship, given that
this is somewhat higher than that seen in the Phase I
trial over the whole dose range. However, these are
non-randomised  data  and  we  must  await  mature
response  data  from  the  Phase  III  trial. Tumour
shrinkage  may  occur  very  slowly. Data  presented
recently8 indicate a median of 4 months from start of
treatment to objective remission, with some patients
taking much longer.Often the ￿ rst objective evidence
of response is clinical softening of tumour masses and
radiological  ‘liquefaction’, i.e., tumours  becoming
cystic.
It is known that certain KIT mutations (exon 11)
are favourable for response to imatinib while patients
with  the  wild-type  gene  are  much  less  likely  to
respond.A recent paper showed that KIT activation,
as  indicated  by  a  characteristic  gene  expression
pattern, can occur in the absence of KIT immuno-
histochemical staining.12 Perhaps in the future it will
be appropriate to carry out mutational analysis prior
to initiating treatment. Similarly, it appears that that
the likelihood of response can be predicted with some
accuracy using an early PET scan.
Recommedations
See algorithm in Fig 1.
￿ The diagnosis of GIST needs to be made by suit-
ably experienced pathologists.The choice of anti-
body  for  assessment  of  CD117  expression
appears to be important and use of the DAKO
antibody has been recommended in all large trials
performed to date, preferably without antibody
retrieval  techniques, which  can  result  in  false-
positives. It must be emphasised that  the diag-
nosis of GIST does not rest on CD117 expression
alone. It  should be  made  by  pathologists  with
experience of the disease, and needs to take into
account  morphology  and  other  immunohisto-
chemical  markers, such  as  CD34. In  addition,
albeit  rarely, CD117  negative  GIST  has  been
described. Recent  data  indicate  that  such
tumours may still have activating KIT mutations.
￿ Like other sarcomas,GISTs should be managed in
an appropriate multidisciplinary setting, ideally a
Multidisciplinary  Sarcoma Team. The  principal
treatment for GIST is surgery,which may be cura-
tive, but patients should be discussed pre-opera-
tively and some might bene￿ t from pre-operative
treatment if operability is borderline.It is likely that
4–6 months’ of  treatment would be required in
order to obtain maximum bene￿ t from pre-opera-
tive therapy. Operations should be performed by
surgeons with experience in the management of
sarcomas.
￿ Imatinib should be considered the treatment of
choice for patients with advanced unresectable or
metastatic  GIST. It  would  be  appropriate  for
healthcare  commissioning  bodies  to  designate
centres for the treatment of GIST with imatinib
in  order to  ensure that  adequate  experience is
gained with  this  expensive drug in such a  rare
tumour type.The drug has signi￿ cant toxicity and
requires careful monitoring.There is still much to
be learnt about its optimal delivery and it is antic-
ipated  that  further  trials  will  be  conducted to
explore the biology of the disease in relation to its
response to imatinib, and to  de￿ ne the  role of
adjuvant and pre-operative therapy.
￿ Patients with advanced disease should be treated
before they develop severe cachexia.As with other
anticancer agents, the  incidence of  side  effects
correlates with declining performance status and
earlier treatment is likely to be both better toler-
ated  and more effective. It  may  also  delay  the
emergence of drug resistance.
￿ Currently  the  recommendation  would  be  to
initiate treatment with imatinib given at a dose of
400 mg daily P.O.with food.Higher doses may be
given in the event of a poor response or relapse
after initial response,but should not be continued
beyond 8 weeks in the absence of clear cut clin-
ical and radiological bene￿ t.These recommenda-
tions  may  be  modi￿ ed  in  the  light  of  mature
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Fig. 1. Algorithm for management of GIST.References
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